NCT06609473 Proof-of-Concept Testing of the Cardiovascular Health Equity Through Food (CHEF) Intervention in Childhood Cancer Survivors
| NCT ID | NCT06609473 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | Childhood Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 17 participants |
| Start Date | 2025-04-07 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 17 participants in total. It began in 2025-04-07 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of the Cardiovascular Health Equity Through Food (CHEF) program is to make it easier for participants and families to cook and eat healthy foods during and following childhood cancer treatment with the long-term goal of supporting heart health.
Eligibility Criteria
Inclusion Criteria: * Child with any primary cancer diagnosis (non-relapsed, non-secondary malignancy) who has received cancer-directed therapy that includes chemotherapy and/or radiation therapy; * Child is within one of the following time windows: 1. Among those receiving chemotherapy, any time from start of last planned cycle of chemotherapy until 12 months from completion of chemotherapy; 2. Among those receiving radiation therapy alone or radiation and surgery, any time from completion of radiation until 12 months post completion; * Child has 1 or more cardiovascular risk factor (defined as any of: body mass index ≥ 85th percentile; systolic or diastolic blood pressure ≥90th percentile; dyslipidemia \[triglycerides ≥150 mg/dL, total cholesterol ≥200 mg/dL, LDL cholesterol ≥130 mg/dL, HDL cholesterol ≤40 mg/dL\]; impaired glucose metabolism \[fasting glucose ≥100 mg/dL, hemoglobin A1c ≥5.7%\]; anthracycline exposure ≥100 mg/m2; or any radiation exposure to chest, brain, thoracic spine, or total body); * Child is ≤18 years of age at time of enrollment, or over 18 years of age but under medical guardianship; * Parent/guardian screened positive for food insecurity.\* \*Assessed through validated 2-item food insecurity screen. Exclusion Criteria: * Patient received only surgery, or watchful waiting/surveillance, for cancer- directed therapy; * Foreign national family receiving cancer care as an embassy-pay patient.
Contact & Investigator
Rahela Aziz-Bose, MD
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT06609473 clinical trial?
This trial is open to participants of all sexes, up to 18 Years, studying Childhood Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06609473 currently recruiting?
Yes, NCT06609473 is actively recruiting participants. Contact the research team at rahela_aziz-bose@dfci.harvard.edu for enrollment information.
Where is the NCT06609473 trial being conducted?
This trial is being conducted at Boston, United States, Boston, United States.
Who is sponsoring the NCT06609473 clinical trial?
NCT06609473 is sponsored by Dana-Farber Cancer Institute. The principal investigator is Rahela Aziz-Bose, MD at Dana-Farber Cancer Institute. The trial plans to enroll 17 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.